Response categorized using modified IMWG 2016 criteria. Urine testing was not routinely done; only serum M-protein levels were used when determining response. Complete Response(CR)= negative immunofixation on the serum + absence of any soft tissue plasmacytomas + <5% plasma cells in bone marrow aspirates. Very Good Partial Response(VGPR) = serum detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein. Partial Response(PR) = ≥50% reduction of serum M-protein. If the serum is unmeasurable, a > 50% decrease in the difference between involved and uninvolved FLC levels is required. Stable Disease (SD) = not meeting criteria for CR, VGPR, PR, or progressive disease. Progressive Disease (PD) = >25% increase from lowest response value in serum M-protein (the absolute increase must be >0.5 g/dL), or definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas.

The time from the start of BLENREP treatment to the date of first occurrence of response (partial response or better).

The time from the start of BLENREP treatment to the date of the best response achieved (partial response or better).

The time from the first date of PR or better to the earliest of documented disease progression, end of BLENREP treatment, death, lost to followup or end of study timeframe.

The time from the start of BLENREP treatment until the earliest of documented disease progression (according to IMWG response criteria or clinician assessment), end of BLENREP treatment, death, lost to followup or end of study timeframe.

Summary report of patient status at the end of the study period. Duration of survival was calculated, however, median survival time for OS has not yet been reached, and therefore is not reported here.

Number of participants receiving treatment for ocular toxicity during BLENREP therapy, as categorized by type of treatment.

Distress is measured on a scale of 0-10 on the National Comprehensive Cancer Network Distress Thermometer (NCCN DT). A score of 0 represents no distress, and a score of 10 represents worst possible distress. Actionable distress is defined as a NCCN DT score of 4 or higher, and is aligned with the medical practice guidelines for management of distress in cancer patients.The median (min, max) distress score across patients is reported.

Sources of distress will be assessed using the NCCN DT Problem List by examining the percentage of visits where types of problems are reported. There are five categories of distress from which patients can report problems (practical, family, emotional, physical and other problems). The categories of problems are reported as a number and % of the total number of visits where problem lists are reported.

Sources of distress will be assessed using the NCCN DT Problem List by examining the percentage of visits where types of problems are reported. The problem list includes 39 possible problems from which patients can choose. The problems are reported as a number and % of the total number of visits where problem lists are reported.

To the extent that they are available, HCRU [i.e., radiation therapy, transfusions (red blood cells or platelets), inpatient admissions, treatment-related outpatient visits, emergency department visits, palliative care outpatient visits] that occurred during BLENREP treatment will be summarized by the percentage and frequency distribution of patients with any occurrence of the respective outcome.

Age at Multiple Myeloma Diagnosis

Participants may have more than one diagnostic characteristic of MM.

Subtype of MM by Immunoglobulin - as determined at Diagnosis

Subtype of MM by involved serum free light chain - as determined at Diagnosis

The Revised International Staging System (R-ISS) is a prognostic staging system used to stratify patients with MM based on genetic risk as assessed by fluorescence in-situ hybridization (FISH) and routinely used lab values. The R-ISS system consists of stage I: serum beta2-microglobulin < 3.5 milligram per liter (mg/L), albumin >= 3.5 gram per deciliter (g/dL), standard-risk chromosomal abnormalities (CA) by FISH and normal lactate dehydrogenase level (LDH); stage II: neither R-ISS stage I nor stage III; and stage III: beta2-microglobulin >= 5.5mg/L and either high-risk CA by FISH or high LDH.

High-Risk abnormalities identified by cytogenetic testing at diagnosis. International Myeloma Working Group (IMWG)- defined High Risk is the percentage of patients who had any of the following high risk traits: t(4;14), t(14;16), del(17p).

Standard-Risk abnormalities identified by cytogenetic testing at diagnosis

Represents the number of lines patients were refractory to - Double (2 lines), Triple (3), Quad (4) or Penta (5)

Eastern Cooperative Oncology Group (ECOG) Performance Status as graded by clinician using the following Grades: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory, able to carry out work of light nature. 2: Ambulatory, capable of self-care, unable to carry out work activities. Up and about more than 50% waking hours. 3: Capable of limited self-care, confined to bed/chair more than 50% waking hours. 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed/chair. 5: Dead.

Baseline Renal Impairment - Estimated Glomerular Filtration Rate (eGFR)

Serum Creatinine levels are used here as a measure of renal function. For this study, renal insufficiency is defined as a baseline serum creatinine level of >= 2.0 mg/dL.

Number of participants who discontinued treatment with BLENREP by reason.

Treatment characteristics: Dosing patterns - Number of cycles of treatment with BLENREP therapy - From Treatment initiation to treatment discontinuation or last dose during study period.

Number of participants for whom BLENREP dosing was delayed during treatment as categorized by reason.

Number of participants for whom BLENREP dosing was dose reduced during treatment as categorized by reason.

Response categorized using modified IMWG 2016 criteria. Urine testing was not routinely done; only serum M-protein levels were used when determining response. Complete Response(CR)= negative immunofixation on the serum + absence of any soft tissue plasmacytomas + <5% plasma cells in bone marrow aspirates. Very Good Partial Response(VGPR) = serum detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein. Partial Response(PR) = ≥50% reduction of serum M-protein. If the serum is unmeasurable, a > 50% decrease in the difference between involved and uninvolved FLC levels is required. Stable Disease (SD) = not meeting criteria for CR, VGPR, PR, or progressive disease. Progressive Disease (PD) = >25% increase from lowest response value in serum M-protein (the absolute increase must be >0.5 g/dL), or definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas.

The time from the start of BLENREP treatment to the date of first occurrence of response (partial response or better).

The time from the start of BLENREP treatment to the date of the best response achieved (partial response or better).

The time from the first date of PR or better to the earliest of documented disease progression, end of BLENREP treatment, death, lost to followup or end of study timeframe.

Analyzed only for the 20 patients who achieved PR or better

The time from the start of BLENREP treatment until the earliest of documented disease progression (according to IMWG response criteria or clinician assessment), end of BLENREP treatment, death, lost to followup or end of study timeframe.

Summary report of patient status at the end of the study period. Duration of survival was calculated, however, median survival time for OS has not yet been reached, and therefore is not reported here.

Number of participants with specific ocular events of interest during treatment with BLENREP

Number of Ocular Toxicity Events (Corneal Event or Best-Corrected Visual Acuity Change) per patient, summarized by median (min, max).

Number of participants receiving treatment for ocular toxicity during BLENREP therapy, as categorized by type of treatment.

Distress is measured on a scale of 0-10 on the National Comprehensive Cancer Network Distress Thermometer (NCCN DT). A score of 0 represents no distress, and a score of 10 represents worst possible distress. Actionable distress is defined as a NCCN DT score of 4 or higher, and is aligned with the medical practice guidelines for management of distress in cancer patients.The median (min, max) distress score across patients is reported.

Sources of distress will be assessed using the NCCN DT Problem List by examining the percentage of visits where types of problems are reported. There are five categories of distress from which patients can report problems (practical, family, emotional, physical and other problems). The categories of problems are reported as a number and % of the total number of visits where problem lists are reported.

Sources of distress will be assessed using the NCCN DT Problem List by examining the percentage of visits where types of problems are reported. The problem list includes 39 possible problems from which patients can choose. The problems are reported as a number and % of the total number of visits where problem lists are reported.

To the extent that they are available, HCRU [i.e., radiation therapy, transfusions (red blood cells or platelets), inpatient admissions, treatment-related outpatient visits, emergency department visits, palliative care outpatient visits] that occurred during BLENREP treatment will be summarized by the percentage and frequency distribution of patients with any occurrence of the respective outcome.

Study procedures included recording ocular symptoms reported by patients documented in the clinic notes. These were categorized into blurry vision, dry eyes, photophobia and other symptoms (including foreign-body sensation, "grittiness", "itch/scratchiness", irritation, and tearing). This Data table reports the total number of Ocular Symptoms reported by patients, along with counts and percentage by type of symptom.

The 30 patients in the study reported specific symptoms a total of 192 times at clinic visits. The analysis population is the 192 symptoms reported.

Ocular toxicity as measured by corneal events per the Keratopathy Visual Acuity scale, and graded using belantamab mafodotin REMS [Risk Evaluation and Mitigation Strategies] guidelines. Corneal examination changes from baseline are categorized as normal or grade 1, 2, 3, or 4 and are based on the worst overall finding. Normal: Cornea clear/No change from baseline. Grade 1: Mild superficial keratopathy with or without symptoms. Grade 2: Moderate superficial keratopathy. Grade 3: Severe superficial keratopathy. Moderate/Severe keratopathy could be with or without patchy microcyst-like deposits, sub-epithelial haze (peripheral), or a new peripheral stromal opacity. Grade 4: Corneal epithelial defect (such as corneal ulcer). The Data table reports the total number of corneal events experienced, along with counts and percentage by grade of event.

The 30 patients in the study experienced ocular toxicity (corneal events) a total of 323 times as reported during clinic visits. The analysis population is the 323 events reported.

Clinically Meaningful Event is defined as an event that is grade >= 2 for which BLENREP administration is halted until the event resolves to grade <= 1. Time to resolution is calculated for events that resolved. Unresolved events are those that had not returned to grade <=1 at last contact due to either end of study or lost to ophthalmologic follow-up. There were 64 resolved events for Corneal Events that were analyzed

Ocular toxicity as measured by changes to BVCA as measured per the Keratopathy Visual Acuity scale, and graded using belantamab mafodotin REMS [Risk Evaluation and Mitigation Strategies] guidelines. BVCA changes from baseline are categorized as normal or grade 1, 2, 3, or 4 and are based on the worst overall finding. Normal: No decline from baseline on Snellen Visual Acuity. Grade 1: Decline from baseline of 1 line on Snellen Visual Acuity. Grade 2: Decline from baseline of 2 or 3 lines on Snellen Visual Acuity, and not worse than 20/200. Grade 3: Decline from baseline of more than 3 lines on Snellen Visual Acuity, and not worse than 20/200. Grade 4: Snellen Visual Acuity worse than 20/200. The Data table reports the total number of BVCA changes experienced, along with counts and percentage by grade of change.

The 30 patients in the study experienced ocular toxicity (changes to BVCA) a total of 244 times as reported during clinic visits. The analysis population is the 244 BVCA changes reported.

Clinically Meaningful Event is defined as an event that is grade >= 2 for which BLENREP administration is halted until the event resolves to grade <= 1. Time to resolution is calculated for events that resolved. Unresolved events are those that had not returned to grade <=1 at last contact due to either end of study or lost to ophthalmologic follow-up. There were 44 Resolved events for changes in Best Corrected Visual Acuity that were analyzed.

The number and percentage of patients who were in Hospice Care prior to death. Analyzed for the 10 patients who died as of last follow-up Dec. 1st 2023.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.

Ocular adverse events were collected per participant, not per eye.